BayPine to acquire a majority stake in CenExel.

BayPine, a private investment firm that drives digital transformation in market-leading businesses, agreed to acquire a majority stake in CenExel, a clinical trial site network focused on complex therapeutic areas. Financial terms were not disclosed. CenExel operates a highly differentiated, strategic clinical trial site network with deep expertise in central nervous system research as well as other complex, high-need therapeutic areas. The Company supports critical components of clinical development, including protocol development, patient recruitment and retention, and clinical trial operations and data collection.